COMMUNIQUÉS West-GlobeNewswire

Nu-Med Plus, Inc. Approaches Landmark Certification to Speed New Nitric Oxide Medical Device Approval
31/07/2018
Innovative Nitric Oxide Delivery Device Company Announces Program to Attain ISO 13485 Certification SALT LAKE CITY, July 31, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc . (OTCQB:NUMD), a medical device leader developing [...]
Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer
31/07/2018
Experienced Surgeon and Life Sciences Executive to Lead Medical Affairs, Clinical and Regulatory Operations in Preparation for Potential Commercial Launch of NeoCart® WALTHAM, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- [...]
aTyr Pharma Appoints Jill Broadfoot as Chief Financial Officer
31/07/2018
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]
Aptose to Present at the 2018 Global Congress on Oncology and Cancer
31/07/2018
SAN DIEGO and TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of [...]
PolarityTE, Inc. Announces Alain Adam as Vice President of Sales
31/07/2018
SALT LAKE CITY, July 31, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq: COOL) today announced the appointment of Alain Adam as Vice President of Sales. Mr. Adam will lead the company’s continued development of its [...]
Summary of Calendar for Upcoming Proposed Delcath Rights Offering
31/07/2018
The Company’s Directors and Officers Indicate Intent to Participate in the Rights Offering Once Effective NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology [...]
Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program
31/07/2018
Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program Program aims to counteract antibiotic resistance by use of artificial intelligence in drug development Amsterdam, the Netherlands, [...]
Active Biotech provides update on laquinimod in Huntington's disease
31/07/2018
PRESS RELEASE Lund Sweden, July 31, 2018 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today provided an update regarding the clinical development of laquinimod by Teva Pharmaceutical Industries Ltd. The Phase 2 LEGATO-HD [...]
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period
31/07/2018
PRESS RELEASE Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period TiGenix becomes a wholly owned subsidiary of Takeda Ordinary Shares have been delisted from Euronext Brussels The [...]
Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait
31/07/2018
COMMUNIQUÉ DE PRESSE Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait TiGenix devient donc une filiale propriété exclusive de Takeda Les Actions ordinaires ont été radiées d' [...]
Sanofi: Q2 2018 Performance Positions Sanofi for New Growth Phase
31/07/2018
Paris, July 31, 2018 Q2 2018 Performance Positions Sanofi for New Growth Phase Q2 2018 Change Change at CER H1 2018 Change Change at CER IFRS net sales reported €8,176m -5.7% +0.1% €16,074m -7.2% -0.1% IFRS net income [...]
Sanofi : Après les résultats du T2 2018, Sanofi bien placé pour une nouvelle période de croissance
31/07/2018
Paris, le 31 juillet 2018 Après les résultats du T2 2018, Sanofi bien placé pour une nouvelle période de croissance T2 2018 Variation Variation à TCC S1 2018 Variation Variation à TCC Chiffre d'affaires net IFRS publié [...]
Zealand announces an 85% increase in Soliqua® 100/33/ Suliqua® royalty revenue from first to second quarter of 2018
31/07/2018
Company announcement - No. 19/2018 Zealand announces an 85% increase in Soliqua ® 100/33/ Suliqua® royalty revenue from first to second quarter of 2018 Net sales of Soliqua ® 100/33/ Suliqua® and Lyxumia®/Adlyxin® of [...]
Eckert & Ziegler BEBIG: First Half-Year Results 2018 Published
31/07/2018
Seneffe - Belgium, July 31, 2018, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its half-year results 2018. The report including a selection of consolidated key [...]
Eckert & Ziegler BEBIG: Publication du résultat du premier semestre 2018
31/07/2018
Seneffe - Belgique, 31 juillet 2018, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) a communiqué aujourd'hui son rapport du 1er semestre 2018. Le rapport qui comprend une sélection de [...]
ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018
31/07/2018
Geneva, Switzerland and Boston, MA - July 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]
MDxHealth: SelectMDx Study Demonstrates Cost-effectiveness in US Healthcare System
31/07/2018
NEWS RELEASE REGULATED INFORMATION Data published in Journal of Urology reports over $500 million in potential annual cost savings for the US healthcare system IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 31, [...]
MDxHealth (R) : Une étude démontre la rentabilité du test SelectMDx au sein du système de soins de santé américain
31/07/2018
COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉES Les données publiées dans la revue Journal of Urology indiquent que le système des soins de santé américain pourrait, chaque année, économiser plus de 500 millions de [...]
Fagron NV : Disclosure of received notification
31/07/2018
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2018 - 7:00am (CET) Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron [...]

Pages